Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 7/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134946 | 0.91 | DGAT1 (0.44) | CSNK2A2CSNK2A1DGAT1HRH3MAOB | |
| Hydrochloric Acid SCHEMBL6133784 | 0.86 | CSNK2A2 (0.48) | CSNK2A2CSNK2A1HRH3NR1H4 | |
| Hydrochloric Acid SCHEMBL6135103 | 0.84 | MKNK1 (0.47) | CSNK2A2CSNK2A1HRH3MAOBP2RY14 | |
| SCHEMBL6135605 | 0.84 | CSNK2A2 (0.53) | CSNK2A2CSNK2A1HRH3NR1H4 | |
| Hydrochloric Acid SCHEMBL6135101 | 0.84 | TP53 (0.41) | CSNK2A2CSNK2A1HRH3MAOBP2RY14 | |
| SCHEMBL6133892 | 0.83 | CSNK2A2 (0.42) | CSNK2A2CSNK2A1DGAT1HRH3NR1H4 | |
| Trifluoroacetic Acid SCHEMBL6133865 | 0.83 | MAOB (0.40) | CSNK2A2CSNK2A1DGAT1HRH3MAOB | |
| SCHEMBL6134617 | 0.82 | HDAC3 (0.46) | MAOBSIGMAR1 | |
| SCHEMBL1305330 | 0.79 | SLC18A3 (0.58) | HRH3SIGMAR1SLC18A3 | |
| SCHEMBL6134824 | 0.79 | HRH1 (0.48) | HRH3MAOBSIGMAR1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | CSNK2A2 1527/4885CSNK2A1 961/4885DGAT1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.